Margaret I Liang1, Sarah S Summerlin2, Christina T Blanchard3, Teresa K L Boitano4, Warner K Huh1, Smita Bhatia5, Maria Pisu6. 1. Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Alabama at Birmingham, Birmingham, AL. 2. School of Medicine, University of Alabama at Birmingham, Birmingham, AL. 3. Center for Women's Reproductive Health, Department of Obstetrics & Gynecology, University of Alabama at Birmingham, Birmingham, AL. 4. Department of Obstetrics & Gynecology, University of Alabama at Birmingham, Birmingham, AL. 5. Division of Pediatric Hematology & Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL. 6. Division of Preventive Medicine, Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL.
Abstract
PURPOSE: Our objective was to measure the trajectory of financial distress and to determine its relationship with quality of life (QOL) among patients with cancer. MATERIALS AND METHODS: We conducted a longitudinal survey of patients with gynecologic cancer starting a new line of systemic therapy at baseline, 3 months, and 6 months. Financial distress was measured using a Comprehensive Score for Financial Toxicity (COST) < 26, and QOL was measured using Functional Assessment of Cancer Therapy-General (FACT-G) with lower scores indicating worse responses. One-way repeated analysis of variances, generalized estimating equation models, and correlation coefficients were used to evaluate financial distress and QOL over time. RESULTS: There were 90 of 121 (74%) baseline participants with a 6-month follow-up. The average age was 60 years, 29% were African-American, 57% had an annual income < $40,000 in US dollars, and 6% were uninsured. At baseline, 54% of patients screened positive for financial distress, which was unchanged at 3 months (50%, P = .27) but decreased at 6 months (46%, P = .04) compared with baseline. There was no change in average COST (23.6, 25.1, 25.6; P = .33) or FACT-G (70.8, 71.0, 72.8; P = .68) over time. Less financial distress was moderately correlated with better QOL (r = 0.63, 0.61, 0.60) at each time point. The presence of financial distress was associated with a 16-point decrease in FACT-G QOL score over time. CONCLUSION: Upfront screening with COST identified 90% of patients who experienced financial distress, and COST did not change significantly over time. More severe financial distress was moderately correlated with worse QOL, and its presence was associated with a clinically meaningful 16-point decrease in QOL.
PURPOSE: Our objective was to measure the trajectory of financial distress and to determine its relationship with quality of life (QOL) among patients with cancer. MATERIALS AND METHODS: We conducted a longitudinal survey of patients with gynecologic cancer starting a new line of systemic therapy at baseline, 3 months, and 6 months. Financial distress was measured using a Comprehensive Score for Financial Toxicity (COST) < 26, and QOL was measured using Functional Assessment of Cancer Therapy-General (FACT-G) with lower scores indicating worse responses. One-way repeated analysis of variances, generalized estimating equation models, and correlation coefficients were used to evaluate financial distress and QOL over time. RESULTS: There were 90 of 121 (74%) baseline participants with a 6-month follow-up. The average age was 60 years, 29% were African-American, 57% had an annual income < $40,000 in US dollars, and 6% were uninsured. At baseline, 54% of patients screened positive for financial distress, which was unchanged at 3 months (50%, P = .27) but decreased at 6 months (46%, P = .04) compared with baseline. There was no change in average COST (23.6, 25.1, 25.6; P = .33) or FACT-G (70.8, 71.0, 72.8; P = .68) over time. Less financial distress was moderately correlated with better QOL (r = 0.63, 0.61, 0.60) at each time point. The presence of financial distress was associated with a 16-point decrease in FACT-G QOL score over time. CONCLUSION: Upfront screening with COST identified 90% of patients who experienced financial distress, and COST did not change significantly over time. More severe financial distress was moderately correlated with worse QOL, and its presence was associated with a clinically meaningful 16-point decrease in QOL.
Authors: Margaret I Liang; Maria Pisu; Sarah S Summerlin; Teresa K L Boitano; Christina T Blanchard; Smita Bhatia; Warner K Huh Journal: Gynecol Oncol Date: 2019-11-23 Impact factor: 5.482
Authors: D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon Journal: J Clin Oncol Date: 1993-03 Impact factor: 44.544
Authors: Mahasin S Mujahid; Nancy K Janz; Sarah T Hawley; Jennifer J Griggs; Ann S Hamilton; Steven J Katz Journal: Breast Cancer Res Treat Date: 2009-04-10 Impact factor: 4.872
Authors: Angela G E M de Boer; Tyna K Taskila; Sietske J Tamminga; Michael Feuerstein; Monique H W Frings-Dresen; Jos H Verbeek Journal: Cochrane Database Syst Rev Date: 2015-09-25
Authors: Jonas A de Souza; Bonnie J Yap; Kristen Wroblewski; Victoria Blinder; Fabiana S Araújo; Fay J Hlubocky; Lauren H Nicholas; Jeremy M O'Connor; Bruce Brockstein; Mark J Ratain; Christopher K Daugherty; David Cella Journal: Cancer Date: 2016-10-07 Impact factor: 6.860
Authors: Emeline M Aviki; Bridgette Thom; Kenya Braxton; Andrew J Chi; Beryl Manning-Geist; Fumiko Chino; Carol L Brown; Nadeem R Abu-Rustum; Francesca M Gany Journal: Support Care Cancer Date: 2021-11-25 Impact factor: 3.359